Trial Profile
Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Aug 2019
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PREDICT
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.
- 20 Mar 2018 New trial record